Monopar Pharma (MNPR) Net earnings per share growth forecast for next year

Corporate company logo of Monopar Therapeutics (MNPR)

Monopar Therapeutics (MNPR) centers in the US are developing agents to reduce chemotherapy toxicity. The trend in the company's EPS forecast reflects current dynamics, where -36.80 describes the current status of the metric. The integration of drugs into standard treatment protocols guarantees future cash inflows. The business currently relies on external investments, as market pricing will only emerge upon the completion of clinical trials.

Monopar Pharma (MNPR): Net earnings per share growth forecast for next year from 07/04/2022 to 11/15/2026

Summary analytical data breakdowns for Monopar Pharma (MNPR)

- share price and consensus valuation forecast:
Fundamental company analysis:Monopar Therapeutics
Finished products of Monopar Therapeutics Inc

For Monopar Therapeutics, which develops targeted oncology drugs, this indicator serves as a gauge of market optimism regarding future profitability. The metric aggregates analyst forecasts for earnings per share growth rates, reflecting the expected efficiency of clinical protocols. The current consensus EPS growth forecast for the coming year demonstrates the speed at which valuations are adapting to news regarding therapy toxicity. This trend determines the investment attractiveness of the biopharmaceutical business.

Competitor analysis for Monopar Therapeutics

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Inhibrx Biosciences Inc INBX|I-Mab - Net earnings per share growth forecast for next year|FENC - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year herontx.com|NVCT: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Coherus CHRS|Expected earnings per share growth for next year CRBP|Expected net earnings per share growth next year Cardiff Oncology CRDF|Expected earnings per share growth for next year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Expected earnings per share trend next year|Lixte Biotechnology - Expected earnings per share growth for next year|Projected earnings per share increase next year CTXR (Citius Pharma)|Cellectar - Earnings growth forecast for next year|Expected earnings per share trend next year BLRX (BioLineRx Corp)|CANF: Earnings growth forecast for next year|Expected net earnings per share growth next year Aprea (APRE)|Net earnings per share growth forecast for next year kaziatherapeutics.com|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)